GLP‑1s in Advanced CKD and Dialysis: How Far Can We Go Safely?

Managing type 2 diabetes in people with advanced chronic kidney disease (CKD) and end-stage kidney disease (ESKD) on dialysis presents unique clinical challenges. With the 2026 Standards of Care increasingly shifting the focus toward cardio-renal outcomes, many clinicians are asking: how far can we go safely with GLP‑1 receptor agonists in this population? This article explores the growing role of GLP‑1 advanced CKD dialysis therapy, reviewing current evidence, tolerability strategies, and how to work collaboratively with nephrology for optimal patient care.

Table of Contents

• Understanding GLP‑1 Receptor Agonists in CKD
• Evidence for GLP‑1 Use at Low eGFR and in Dialysis
• Managing GI Side Effects in Advanced CKD
• Coordinating Care With Nephrology
• Practical Prescribing Tips
• Conclusion
• Frequently Asked Questions

Understanding GLP‑1 Receptor Agonists in CKD

GLP‑1 receptor agonists (GLP‑1 RAs) have become central to type 2 diabetes care, offering benefits beyond glycemic control such as weight loss and cardiovascular protection. In advanced CKD, including dialysis, the primary goal extends beyond A1C management to include systemic outcomes. As the 2026 guidelines suggest, using GLP‑1s in this setting is now more about cardiorenal protection than glycemic targets alone.

That said, careful selection and monitoring are essential. Although many GLP‑1 RAs do not require dose adjustments based solely on eGFR, the absence of robust trial data in dialysis patients adds complexity to their use.

Evidence for GLP‑1 Use at Low eGFR and in Dialysis

When prescribing in the GLP‑1 advanced CKD dialysis context, the key question is which agents are safe at very low kidney function. Agents like dulaglutide, semaglutide, and liraglutide have shown safety in patients with eGFR as low as 15 mL/min/1.73 m², although data in dialysis populations remain sparse.

For instance, dulaglutide showed promise in the AWARD-7 trial, maintaining glycemic control and potentially preserving renal function. While these findings are encouraging, real-world use in dialysis must be cautious, individualized, and always done with nephrology input.

Managing GI Side Effects in Advanced CKD

GLP‑1 RAs commonly cause gastrointestinal issues such as nausea and vomiting, especially early in treatment. These can be more problematic in patients with advanced CKD or those on dialysis due to overlapping uremic symptoms and fluid restrictions.

To reduce GI intolerance:

• Start with the lowest available dose and titrate slowly.
• Encourage smaller, low-fat meals to reduce nausea.
• Monitor for dehydration, which can worsen symptoms and kidney function.

If GI symptoms persist, consider switching to another GLP‑1 RA or exploring other drug classes better tolerated by the patient.

Coordinating Care With Nephrology

Because patients with ESKD often have complex medical needs, coordination with nephrologists is critical when prescribing GLP‑1 advanced CKD dialysis therapy. This ensures alignment on treatment goals, lab monitoring, and potential side effects.

Nephrology can offer insights on dialysis timing, residual renal function, and cardiovascular risk stratification. This collaborative approach helps ensure patient safety and therapeutic success.

Practical Prescribing Tips

Here are practical tips for GLP‑1 use in advanced CKD and dialysis:

• Select GLP‑1 RAs with existing data at low eGFR levels.
• Be aware of overlapping GI side effects from other drugs.
• Use CGM or frequent glucose monitoring to track response.
• Focus on broader goals like cardiovascular health and preserving renal function, not just A1C.

More clinical guidance can be found at the ADA’s Standards of Care and through partnerships with nephrology practices.

Conclusion

The use of GLP‑1 advanced CKD dialysis therapies represents a major step forward in diabetes care for high-risk patients. While not without challenges, the cardio-renal benefits of these agents offer meaningful improvements for patients with few other options. With proper agent selection, patient monitoring, and team-based care, GLP‑1s can be safely and effectively used in this complex population.

Frequently Asked Questions

1. Can GLP‑1 receptor agonists be used in dialysis patients?
Yes, cautiously. Although trial data is limited, some GLP‑1s have been used off-label in dialysis patients with close monitoring.

2. Do GLP‑1 RAs require dose adjustments in CKD?
Most do not need dose adjustments solely based on kidney function. Always consult individual product labeling.

3. What can help reduce GI side effects in CKD?
Start low, titrate slowly, avoid fatty foods, and monitor hydration. Adjust or stop therapy if side effects are severe.

4. Should nephrologists be involved in prescribing GLP‑1s?
Absolutely. Coordinating with nephrology ensures safer care and aligns therapy with broader renal management goals.

5. Are GLP‑1s beneficial beyond A1C reduction in CKD?
Yes. Many GLP‑1s provide cardiovascular and renal protection, which is vital in CKD patients.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.